Rivaroxaban is one of the new anti-coagulants that inhibit Factor Xa and rarely cause rectus sheath hematoma and retroperitoneal haemorrhage which are uncommon, life-threatening complications. Here is a case of an elderly patient on rivaroxaban therapy for the stroke prevention in non-valvular atrial fibrillation who developed rectus sheath hematoma and retroperitoneal bleeding.
DOI: https://dx.doi.org/10.4314/ahs.v19i2.55
Cite as: Börekci E. Rectus sheath hematoma and retroperitoneal bleeding due to rivaroxaban: a case report. Afri Health Sci.2019;19(2): 2290-2293. https://dx.doi.org/10.4314/ahs.v19i2.55
